Recent studies in rats have demonstrated that statins may have an inhibitory effect on intracranial aneurysm (IA) development. The purpose of this study was to assess whether long-term statin use is associated with a reduced risk of IA formation in humans.
This was a single-center case-control study that included consecutive patients admitted to the authors' institution between January 1, 2005, and December 31, 2008. A case was defined as a patient with a cerebral angiography–confirmed diagnosis of IA. Three controls were matched to each case based on age, sex, and index year of hospital admission. The primary exposure of interest was cumulative statin use. Conditional logistic regression was used to assess the relationship between statin intake and incidence of IA.
In total, 1200 patients were included in the study. No overall association was found between statin use and incidence of IA formation (OR 1.08, 95% CI 0.69–1.69), nor when dichotomized into hydrophilic and lipophilic user, or between short (≤12-month) and long (≥36-month) duration of intake. Hypertension and smoking significantly increased the risk of IA development (OR 4.02, 95% CI 2.49–6.45, and OR 1.67, 95% CI 1.02–2.72, respectively).
In contrast to recent experimental reports of the association between statins and a reduction of IA formation, the authors' findings suggest that in humans statins may have no significant beneficial effect on IA suppression.
Abbreviations used in this paper: AAA = abdominal aortic aneurysm; BMI = body mass index; IA = intracranial aneurysm; SAH = subarachnoid hemorrhage.
Address correspondence to: Andreas Raabe, M.D., c/o Publication Office, Susan Wieting, Department of Neurosurgery, Inselspital, Bern University Hospital, 3010 Bern, Switzerland. email: susan. email@example.com.
Please include this information when citing this paper: published online November 25, 2011; DOI: 10.3171/2011.10.JNS11153.
AikawaMRabkinESugiyamaSVoglicSJFukumotoYFurukawaY: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation103:276–2832001
AokiTKataokaHIshibashiRNakagamiHNozakiKMorishitaR: Pitavastatin suppresses formation and progression of cerebral aneurysms through inhibition of the nuclear factor kappaB pathway. Neurosurgery64:357–3662009
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet360:7–222002
HuttunenTvon und zu FraunbergMFrösenJLeheckaMTrompGHelinK: Saccular intracranial aneurysm disease: distribution of site, size, and age suggests different etiologies for aneurysm formation and rupture in 316 familial and 1454 sporadic eastern Finnish patients. Neurosurgery66:631–6382010
ShirayaSMiyakeTAokiMYoshikazuFOhgiSNishimuraM: Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis202:34–402009
ShuHBAgranoffABNabelEGLeungKDuckettCSNeishAS: Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappa B subunits in endothelial and epithelial cells. Mol Cell Biol13:6283–62891993
SteinmetzEFBuckleyCShamesMLEnnisTLVanvickle-ChavezSJMaoD: Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg241:92–1012005
SukhijaRAronowWSSandhuRKakarPBabuS: Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol97:279–2802006